# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0001193125-25-303895
**Filing Date:** 2025-12
**Character Count:** 9346
**Document Hash:** e111da6c7350c29f5067c5163554456c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-303895.hdr.sgml**: 20251201

**ACCESSION NUMBER**: 0001193125-25-303895

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 79

**CONFORMED PERIOD OF REPORT**: 20251201

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251201

**DATE AS OF CHANGE**: 20251201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Perspective Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411458152
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 251539800

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-676-0900

**MAIL ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Isoray, Inc.
- **DATE OF NAME CHANGE:** 20181231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** December 01, 2025<br>

------

Perspective Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33407 | 41-1458152 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| c/o Perspective Therapeutics, Inc.<br>2401 Elliott Avenue<br>Suite 320 |  |  |
| Seattle**,** Washington |  | 98121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (206) 676-0900<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CATX | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 8.01 Other Events.
On December 1, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [<u>Corporate Presentation</u>](catx-ex99_1.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PERSPECTIVE THERAPEUTICS, INC.** |
| Date: | December 1, 2025 | By:  | /s/ Joel Sendek |
|  |  |  | Joel Sendek<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![Slide 1](catx-ex99_1s1.jpg)

Corporate Presentation

------

![Slide 2](catx-ex99_1s2.jpg)

------

![Slide 3](catx-ex99_1s3.jpg)

Developing the next generation of targeted therapies

------

![Slide 4](catx-ex99_1s4.jpg)

Higher potency payloads with cancer-specific targeting

------

![Slide 5](catx-ex99_1s5.jpg)

------

![Slide 6](catx-ex99_1s6.jpg)

Upcoming data milestones

------

![Slide 7](catx-ex99_1s7.jpg)

Radiopharmaceutical therapy poised to revolutionize oncology treatmentPerspective's pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

------

![Slide 8](catx-ex99_1s8.jpg)

------

![Slide 9](catx-ex99_1s9.jpg)

Perspective's Innovative Platform

------

![Slide 10](catx-ex99_1s10.jpg)

Perspective's radiopharmaceutical platform optimized for a broader therapeutic window

------

![Slide 11](catx-ex99_1s11.jpg)

Perspective's proprietary chelator has been optimized for lead-based RPTs

------

![Slide 12](catx-ex99_1s12.jpg)

------

![Slide 13](catx-ex99_1s13.jpg)

------

![Slide 14](catx-ex99_1s14.jpg)

Proposed mechanism of action for 212Pb

------

![Slide 15](catx-ex99_1s15.jpg)

Rationale for synergy with immune checkpoint inhibitors

------

![Slide 16](catx-ex99_1s16.jpg)

------

![Slide 17](catx-ex99_1s17.jpg)

Supply Chain and Manufacturing Infrastructure

------

![Slide 18](catx-ex99_1s18.jpg)

On-demand order fulfillment at regional sites to deliver finished products

------

![Slide 19](catx-ex99_1s19.jpg)

------

![Slide 20](catx-ex99_1s20.jpg)

Neuroendocrine Tumors: VMT-⍺-NET

------

![Slide 21](catx-ex99_1s21.jpg)

------

![Slide 22](catx-ex99_1s22.jpg)

------

![Slide 23](catx-ex99_1s23.jpg)

------

![Slide 24](catx-ex99_1s24.jpg)

Trial design: [212Pb]VMT-⍺-NET Phase 1/2a for PRRT naïve neuroendocrine tumors

------

![Slide 25](catx-ex99_1s25.jpg)

Compelling anti-tumor activity

------

![Slide 26](catx-ex99_1s26.jpg)

Durable disease control across all doses

------

![Slide 27](catx-ex99_1s27.jpg)

Signal of sustained anti-tumor activity

------

![Slide 28](catx-ex99_1s28.jpg)

Best-in-class safety profile1

------

![Slide 29](catx-ex99_1s29.jpg)

Select adverse events of special interest

------

![Slide 30](catx-ex99_1s30.jpg)

Mild and generally transient blood creatinine increase

------

![Slide 31](catx-ex99_1s31.jpg)

[212Pb]VMT-α-NET was well-tolerated and demonstrated compelling anti-tumor activity

------

![Slide 32](catx-ex99_1s32.jpg)

Melanoma Program: VMT01/02

------

![Slide 33](catx-ex99_1s33.jpg)

------

![Slide 34](catx-ex99_1s34.jpg)

------

![Slide 35](catx-ex99_1s35.jpg)

------

![Slide 36](catx-ex99_1s36.jpg)

------

![Slide 37](catx-ex99_1s37.jpg)

Trial design: [212Pb]VMT01 Phase 1/2a for metastatic melanoma

------

![Slide 38](catx-ex99_1s38.jpg)

------

![Slide 39](catx-ex99_1s39.jpg)

Treatment emergent adverse events (all grades, occurring in ≥ 2 patients)

------

![Slide 40](catx-ex99_1s40.jpg)

------

![Slide 41](catx-ex99_1s41.jpg)

------

![Slide 42](catx-ex99_1s42.jpg)

------

![Slide 43](catx-ex99_1s43.jpg)

------

![Slide 44](catx-ex99_1s44.jpg)

------

![Slide 45](catx-ex99_1s45.jpg)

PSV359 is active against FAP-α expression on tumor and on stroma

------

![Slide 46](catx-ex99_1s46.jpg)

------

![Slide 47](catx-ex99_1s47.jpg)

------

![Slide 48](catx-ex99_1s48.jpg)

Trial design: [212Pb]PSV359 Phase 1/2a trial

------

![Slide 49](catx-ex99_1s49.jpg)

------

![Slide 50](catx-ex99_1s50.jpg)

General Corporate Information

------

![Slide 51](catx-ex99_1s51.jpg)

------

![Slide 52](catx-ex99_1s52.jpg)

------

![Slide 53](catx-ex99_1s53.jpg)

------

![Slide 54](catx-ex99_1s54.jpg)

------

![Slide 55](catx-ex99_1s55.jpg)

Abbreviations

------

![Slide 56](catx-ex99_1s56.jpg)

APPENDIX

------

![Slide 57](catx-ex99_1s57.jpg)

------

![Slide 58](catx-ex99_1s58.jpg)

NETs trials

------

![Slide 59](catx-ex99_1s59.jpg)

Potential for differentiated profile based on molecular design

------

![Slide 60](catx-ex99_1s60.jpg)

Durable disease control across all doses

------

![Slide 61](catx-ex99_1s61.jpg)

Refractory metastatic melanoma trials

------

![Slide 62](catx-ex99_1s62.jpg)

Daily production at regional sites ensures supply of ready-to-administer product

------

![Slide 63](catx-ex99_1s63.jpg)

------

![Slide 64](catx-ex99_1s64.jpg)

------

![Slide 65](catx-ex99_1s65.jpg)

------

![Slide 66](catx-ex99_1s66.jpg)

------

![Slide 67](catx-ex99_1s67.jpg)

------

![Slide 68](catx-ex99_1s68.jpg)

Perspective's pre-targeting platform